PWA
MGNX icon

Physician Wealth Advisors’s MacroGenics MGNX Stock Holding History

Physician Wealth Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-501
Closed -$637 – 1911
2025
Q1 		$637 Buy
+501
New +$1.31K ﹤0.01% 1319

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Physician Wealth Advisors's MGNX Position: Q2 2025 in Review

Physician Wealth Advisors sold out of MacroGenics (MGNX) in Q2 2025, closing a stake of 501 shares — an estimated $637 sold.

Physician Wealth Advisors first reported a position in MGNX in Q1 2025 and held it in 1 quarter. The position peaked at $637 in Q1 2025. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2025.

  • Physician Wealth Advisors reported no remaining MacroGenics position as of Q2 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 501 MacroGenics shares in Q2 2025, an estimated $637.
  • Physician Wealth Advisors first reported a position in MacroGenics in Q1 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's MacroGenics position peaked at $637 in Q1 2025.
  • 112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2025.

Based on Physician Wealth Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.